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Regulatory T cells (Treg) can show plasticity whereby FOXP3 expression, the master transcription factor for Treg suppressor
function, is lost and proinﬂammatory cytokines are produced. Optimal FOXP3 expression strongly depends on hypomethylation
of the FOXP3 gene. 5-Azacytidine (Aza) and its derivative 5-aza-2′-deoxycytidine (DAC) are DNA methyltransferase inhibitors
(DNMTi) that are therapeutically used in hematological malignancies, which might be an attractive strategy to promote Treg
stability. Previous in vitro research primarily focused on Treg induction by DAC from naïve conventional CD4+ T cells (Tconv).
Here, we examined the in vitro eﬀect of DAC on the stability and function of FACS-sorted human naturally occurring
CD4+CD25high FOXP3+ Treg. We found that in vitro activation of Treg in the presence of DAC led to a signiﬁcant inhibition of
Treg proliferation, but not of Tconv. Although Treg activation in the presence of DAC led to increased IFNγ expression and
induction of a Thelper-1 phenotype, the Treg maintained their suppressive capacity. DAC also induced a trend towards increased
IL-10 expression. In vivo studies in patients with hematological malignancies that were treated with 5-azacytidine (Vidaza)
supported the in vitro ﬁndings. In conclusion, despite its potential to increase IFNγ expression, DAC does preserve the suppressor
phenotype of naturally occurring Treg.
1. Introduction
Regulatory T cells (Treg) are important for homeostasis
of the immune system [1]. Immune regulation by Treg
depends on the stability of these cells [1, 2], which in turn
is controlled by stable expression of the transcription factor
FOXP3 [3]. In the past, we have shown that Treg reveal plas-
ticity as indicated by loss of FOXP3 expression and gain of
proinﬂammatory cytokine (IL-17a, IFNγ) production [4].
Stable FOXP3 expression requires hypomethylation of
CpG-rich regions of the FOXP3 gene, which is known as
Treg-speciﬁc demethylated region (TSDR) [5–8]. Treg insta-
bility and plasticity have been demonstrated in a number
of immune-related pathologies and are thought to pro-
mote chronic inﬂammation [9–12]. Demethylating agents,
such as the DNA methyltransferase inhibitor (DNMTi)
5-azacytidine (Vidaza, Aza) and its derivative 5-aza 2′-deox-
ycytidine (decitabine, DAC), are used in the treatment of
hematological malignancies and seem an attractive therapeu-
tic strategy to promote Treg stability. Aza and DAC have
relatedmechanisms of action, including depletion of DNMTs
and hypomethylation of DNA [13, 14]. Aza/DAC shows
immunomodulatory potential in vitro and in vivo and have
been shown to induce demethylation of the FOXP3 gene
[15, 16]. Administration of DAC in experimental mouse
models of inﬂammation (lung inﬂammation [17–19], diabetes
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[20], colitis [15], multiple sclerosis [21], and GvHD [22])
revealed promising eﬀects on health outcomes. In most of
these in vivo models, administration of DAC led to an
increase in Treg numbers [17, 19, 21, 22] and inhibition
of eﬀector cells [21]. In a variety of in vitro studies, stimu-
lation of T cells in the presence of DAC led to an increased
expression of FOXP3 [15, 23–26] and hypomethylation of
the FOXP3 gene and promoter [15, 22, 24]. Most of these
studies focused on the induction of FOXP3 expression in
conventional (CD4+CD25−) T cells [23, 24, 26]. Although
DAC treatment induced FOXP3 expression in human
CD4+CD25− conventional T cells, it is still unclear if DAC
induced suppressor potential in these cells [15, 24].
In the clinic, DAC/Aza are used to treat the hematologi-
cal malignancies myelodysplastic syndrome (MDS), acute
myeloid leukemia (AML), and chronic myelomonocytic leu-
kemia (CMML). Overall response rates for Aza and DAC are
similar [14]. The working mechanism in these patients is not
fully understood, but is supposed to be based on upregulation
of antitumor genes [27]. So, on the one hand experiments
and clinical data show antitumor properties of these drugs,
while other experiments show anti-inﬂammatory properties.
In MDS, the immune response is altered; previous studies
have shown polyclonal/oligoclonal expansion of CD4+ and
CD8+ T cells in both blood and bone marrow [28, 29],
changes in the numbers of Treg [30–32], an increase in
IL-17A-producing T cells [31], and immune-mediated
autologous cytotoxicity against hematopoietic precursor
cells [33]. The latter has been proposed to lead to autoimmune
myelosuppression and ineﬀective hematopoiesis [33, 34].
Treg seem to have a role in MDS since in low-risk MDS Treg
numbers are reduced, while in high-risk MDS Treg numbers
are increased and appear associated with a poor prognosis
[35]. Inﬂuencing Treg function and stability might be one of
the ways in which Aza/DAC sorts its eﬀect in hematological
malignancies. However, in patients treated with DAC, con-
ﬂicting observations were reported regarding the eﬀect of
DAC both on CD4+ FOXP3+ cell numbers and on IFNγ
and IL-17 production by T cells [23, 26, 36].
Since no data is available on the eﬀect of DAC on
FOXP3+ Treg stability, suppressive capacity, and function
of freshly isolated human naturally occurring CD4+CD25high
FOXP3+ Treg, we here focused on the in vitro eﬀect of DAC
on the stability and suppressor function of these cells. To put
our in vitro ﬁndings into clinical perspective, we studied
FOXP3, Helios, and cytokine expression in CD4+ T cells in
peripheral blood of patients with hematological malignancies
treated with subcutaneous infusion of Vidaza.
2. Methods
2.1. Patients and Healthy Controls. Peripheral blood (buﬀy
coats) from healthy blood donors was obtained from the
blood bank (Sanquin, the Netherlands). Intermediate/high-
risk IPSS (International Prognostic Scoring System) patients
aﬀected by myeloid dysplastic syndromes(MDS), acute
myeloid leukemia (AML), and chronic myelomonocytic
leukemia (CMML) (n = 14) were treated by s.c. injections
of 75mg/m2/day Vidaza on days 1–7 of a 28-day treatment
cycle. 10mL ACDA blood was collected at the start and after
7 days of treatment in the ﬁrst and ﬁfth treatment cycles.
PBMCs were isolated using Lymphoprep (Axis-Shield,
Dundee, UK) density isolation. Informed consent was
obtained from all patients and healthy blood donors
according to the Declaration of Helsinki. The patient study
was approved by the METOPP committee (NIPMS-VS-
NETH-001, approval number: 469). Patient characteristics
are available in Supplemental Table 1.
2.2. Cell Isolation and Culture of Cells. Treg and Tconv were
isolated from healthy volunteers. CD4+ T cells were isolated
using RosetteSep™ Human CD4+ T cell enrichment Cocktail
(StemCell™ Technologies, Vancouver, Canada) according to
the manufacturer’s instructions. Thereafter, CD4+ T cells
were labeled with anti-CD25-PE-Cy7 (BC96, eBioscience,
San Diego, USA) antibodies to FACS-sort (Aria BD, Franklin
Lakes, New Jersey, USA) CD4+CD25− (Tconv) and CD4+-
CD25high (Treg). Sorted cells were typically more than 96%
pure CD25high cells. Gating strategy is shown in Supplemental
Figure 2. Cells were cultured as described previously [37]. In
brief, isolated T cells were stimulated with anti-CD3/CD28-
mAb-coated beads (T cell expanders, Dynal Biotech, Oslo,
Norway), at a bead : cell ratio of 1 : 5 and 100U recombinant
IL-2 (rIL-2, Proleukin, Cetus, Amsterdam, The Netherlands).
When indicated, 5-aza-2′-deoxycytidine (DAC, 0.01–
100μM/mL, Sigma-Aldrich, St. Louis, Missouri, USA) and/
or IL-1β (50 ng/mL, Invitrogen, Waltham, Massachusetts,
USA) was added at the start of the cultures.
To study the suppressive capacity of Treg and Tconv that
were cultured for 7 days in the presence of DAC, a 5(6)-
carboxyﬂuorescein diacetate N-succinimidyl ester- (CFSE-)
based coculture suppression assaywas performed as described
previously [37]. Brieﬂy, decreasing amounts of Treg were cul-
tured with CFSE-labeled autologous T cells. After 4 days,
CFSE dilution of the CFSE-labeled T cells was measured
using ﬂow cytometry.
2.3. FlowCytometry andAntibodies.Cellswere phenotypically
analyzed by multicolor ﬂow cytometry (Navios, Beckman
Coulter, California, USA). The following cell surface markers
were used: anti-CD4-PE-Cy5.5 (MT310, Dako, Santa Clara,
California, USA) or anti-CD4-AF700 (RPA-T4, eBioscience),
anti-CD25-Pe-Cy7 (BC96, eBioscience) or anti-CD25-APC
(2A3, BD), anti-CD45-KO (J33, Beckman Coulter), anti-
CD196/CCR6-PE (∗11A9, BD), CD183/CXCR3-PerCP5.5
(G025H7, BioLegend, San Diego, California, USA), and
CD194/CCR4-PE-Cy7 (BD). To analyze the intracellular
expression of FOXP3, Helios, and Ki67, the cells were ﬁxed
and permeabilized (Fix-Perm, eBioscience) after surface
staining and labeled with anti-FOXP3-eFluor450 (PCH101,
eBioscience), Ki67-Alexa-Fluor 488 (B56, BD bioscience),
and Helios-Alexa-Fluor 647 (22F6, BioLegend). Intracellular
cytokine production was studied after 4 hours of stimulation
with PMA (12.5 ng/mL) and ionomycin (500 ng/mL) in
the presence of Brefeldin A (5μg/mL) (all Sigma-Aldrich).
After ﬁxation and permeabilization, cells were stained by
the following antibodies: anti-IFNγ-FITC (4S.B3, BD),
anti-IL-17a-PE (EBIO64CAP17, eBioscience), and anti-IL-
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10-APC (JES3-19F1, BD). Cell viability was analyzed
using Fixable Viability Dye eFluor 780 (Cat nr 65-0865,
eBioscience). Flow cytometry data were analyzed using
Kaluza (version 1.3) software (Beckman Coulter). Cells are
gated on lymphocytes based on CD45 staining and forward/
side scatter plots. Marker settings were based on isotype con-
trols or unstained cells. Unless mentioned otherwise, graphs
present data of day 8.
2.4. Real-Time Quantitative Reverse Transcriptase PCR
(RT-qPCR). T cells were cultured as indicated above. At
day 4 of the cultures, the cells were harvested and total
RNA was extracted by using the RNeasy Plus Micro kit
(Qiagen) followed by cDNA synthesis using the Super-
Script III First-Strand Synthesis System and Oligo(dT)20
primers (Thermo Fisher Scientiﬁc) according to the man-
ufacturer’s instruction. TaqMan gene expression assays
and primers were purchased from Thermo Fisher Scientiﬁc
(Supplemental Table 2). The samples were normalized to
the CT values of human HPRT1 (endogenous control).
RT-qPCR data were analyzed using the relative quantiﬁca-
tion app, and 2−ΔCT values were displayed as relative gene
expression (Thermo Fisher Scientiﬁc Cloud).
2.5. Statistics. Statistical analysis was performed using
GraphPad Prism version 5.03. The Wilcoxon signed-rank
test (2-tailed) was used to test for signiﬁcance of the ﬁndings
for in vitro studies. For the patient study, paired t-tests were
used. Diﬀerences with a p value of <0.05 were considered sig-
niﬁcant and are indicated with an asterisk (∗ ). p < 0 01 is
indicated as ∗∗ .
3. Results
3.1. DAC Promotes Expression of FOXP3 in Treg and Tconv
without Altering the Expression of Helios. Previous studies
reported the increased expression of FOXP3 in conventional
T cells (Tconv) stimulated in the presence of DAC, but these
cells did not reveal suppressive capacity [24, 26]. Here, we
examined the eﬀect of DAC on the naturally occurring
CD4+ CD25high FOXP3+ Treg population. CD4+CD25high
cells were isolated by high-purity FACS sorting; >90% of
sorted Treg were CD25+FOXP3+ (Supplemental Figure 1a).
Next, dose-response experiments were performed to select
the optimal dose of DAC with regard to viability of the cells.
FACS-sorted Treg as well as Tconv were stimulated with
anti-CD3/CD28 mAb-coated beads, and recombinant
human IL-2 (rIL-2) was exogenously added, in the absence
or presence of 0.01–100μM DAC, and cultured for 8 days.
The addition of DAC in concentrations up to 1μM to either
stimulated Treg or Tconv did not lead to signiﬁcant cell death
at day 8 of culture (Supplemental Figure 2). Consequently, a
dose of 1μM was used in subsequent experiments. This
corresponds with peak concentrations measured in patients
treated with decitabine [38].
The transcription factors FOXP3 and Helios are impor-
tant for Treg suppressor function [39]. Here, we assessed
the expression of intracellular FOXP3 and Helios in both
Treg and Tconv upon anti-CD3/CD28 stimulation in the
presence of DAC at day 8 of culture. (Gating strategy is shown
in Supplemental Figure 1b.) In Treg, DAC supplementation
did not aﬀect the percentage of FOXP3-expressing cells
(78.18%± 21.13 versus DAC 85.38%± 4.86, NS), but did lead
to a signiﬁcant increase in FOXP3 expression levels (MFI
medium 6.63± 2.56 versus DAC 8.41± 2.67 p = 0 0156)
(Figure 1(a)). Regarding Helios expression in Treg, addi-
tion of DAC led to slightly lower but nonsigniﬁcant changes
in the percentages of Helios-expressing cells (medium
54.68%± 3.33 versus DAC 44.90%± 5.34, NS) and Helios
expression levels (MFI medium 12.78± 1.80 versus DAC
10.73± 1.48, NS) (Figure 1(b)). As shown previously
[15, 23, 24], stimulation of FACS-sorted Tconv in the pres-
ence of DAC led to a signiﬁcant upregulation of both
FOXP3-expressing cells (medium 40.70%± 14.95 versus
DAC 70.43%± 10.22, p = 0 0078) and FOXP3 expression
levels (MFI medium 2.86± 1.21 versus DAC 7.62± 3.36
p = 0 0078) (Figure 1(a)). In these activated Tconv, the
expression levels of Helios were low (MFI 2.50± 1.34)
and were not aﬀected by DAC treatment (5.77± 1.92)
(Figure 1(b)). Thus, DAC treatment of both Treg and Tconv
resulted in an increased FOXP3 expression. The typically high
expression levels of Helios in naturally occurring Treg were
not aﬀected by DAC; neither did Tconv upregulate Helios
expression upon DAC treatment. The increase in FOXP3
expression by DAC was conﬁrmed on the gene expression
level using qPCR (Figure 1(c)).
3.2. DAC Suppresses Proliferation of Regulatory T Cells but
Does Not Alter Their Suppressive Capacity.We then analyzed
the eﬀect of DAC on the proliferative capacity of stimulated
Treg versus Tconv at day 8 of culture. Addition of 1μM of
DAC signiﬁcantly inhibited proliferation of Treg as mea-
sured by % Ki67 expression (medium 78.37%± 22.78 versus
DAC 65.51%± 20.06, p = 0 0156), but not of Tconv (medium
98.93%± 4.85 versus DAC 92.07%± 6.99, p = 0 0547)
(Figures 2(a) and 2(b)). Cell counts before and after culture
conﬁrmed reduced proliferation, which was more prone for
Treg as compared to Tconv (data not shown). To determine
whether Treg were still suppressive despite inhibited prolifer-
ation, a CFSE-based coculture suppression assay was
conducted using FACS-sorted Treg that were stimulated
and cultured for 8 days in the absence and presence of
DAC. DAC-treated Treg kept their suppressive capacity
(Figures 2(c) and 2(d)). Although DAC treatment led to an
increased FOXP3 expression by Tconv, it did not result in
suppressive capacity (not shown), such as that reported
previously [24].
3.3. Regulatory T Cell Activation in the Presence of DAC
Results in Increased IFNγ and IL-10 Expression. The eﬀect
of DAC on cytokine expression by T cells is not clear; in some
studies, DAC results in upregulation of Th1- and Th17-
related cytokines [24], while other studies show downregula-
tion of these cytokines in T cells [21, 23]. To analyze the eﬀect
of DAC on the cytokine-producing potential and diﬀerentia-
tion of freshly isolated human Treg versus Tconv, these cells
were cultured for 8 days with anti-CD3/CD28 mAb-coated
beads and rIL-2 in the absence or presence of DAC.
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Subsequently, expression of intracellular IFNγ, IL-17A, and
IL-10 was analyzed by ﬂow cytometry. Addition of DAC
led to a signiﬁcantly increased IFNγ expression by the stimu-
lated Treg (medium 6.59%± 5.71 versus DAC 12.45%± 8.53,
p = 0 0313), as well as Tconv (medium 10.51%± 15.83 versus
DAC 25.55%± 20.48, p = 0 0313). Also, a trend towards
increased IL-10 expression was observed in both Tconv
(medium 1.51%± 1.33 versus DAC 3.70%± 3.38, p = 0 0625
(NS)) and Treg (medium 7.74% versus 6.56 versus DAC
11.37%± 7.15, p = 0 0938 (NS)). The cytokine-producing
potential of IL-17A was not inﬂuenced by DAC treatment
(Figures 3(a)–3(c)). Upon in vitro culture of Treg, a cell
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Figure 1: Eﬀect of DAC on FOXP3 andHelios expression of CD4+ Treg and Tconv. Flow cytometric analysis of the intracellular expression of
(a) FOXP3 and (b) Helios in αCD3/αCD28+ 100U rIL-2-stimulated FACS-sorted Treg and Tconv in the absence or presence of 1 μMof DAC,
at day 8 of culture. Cells were gated on the expression of CD45 and CD4. FOXP3 gate settings are based on freshly isolated Tconv and Treg.
Representative histograms showing percentage positive cells (%) and median ﬂuorescence intensity (MFI) are presented. Cumulative data
presenting the percentage of positive cells and MFI of cells isolated from n = 4 – 7 blood donors are shown. (c) RT-qPCR analysis of
FOXP3 expression in isolated CD4+ T cells stimulated with αCD3/αCD28+ 100U rIL-2 in the absence or presence of 1 μM of DAC, on
day 4 of culture. The samples were normalized to the CT values of human HPRT1 (endogenous control), and 2
−ΔCT values are displayed.
N = 5 Wilcoxon signed-rank test, 1-tailed, ∗p < 0 05, ∗∗p < 0 01
4 Journal of Immunology Research
95.56 % 91.26 %
91.75 % 80.62 %
훼CD3/훼CD28
+IL-2
Ki67
FCS
Ki67
FCS
Tconv
Treg
Day 0 Day 8 medium Day 8 DAC
1000
800
600
400
200
0
100 101 102 103
1000
800
600
400
200
0
100 101 102 103
1000
800
600
400
200
0
100 101 102 103
1000
800
600
400
200
0
100 101 102 103
1000
800
600
400
200
0
100 101 102 103
1000
800
600
400
200
0
100 101 102 103
(a)
⁎
Medium
DAC (1 휇M)
Tconv Treg
0
50
100
%
 K
i6
7+
 c
ell
s
(b)
CFSE
Single cells CFSE labeled Gating divided cells
Medium
DAC
1:1 2:1 4:1
17.60% 33.08% 60.16%
16.24% 22.86% 48.82%
58.74% Control 
(no Treg)
100 101 102 103
100
80
60
40
20
0
100 101 102 103
100 101 102 103100 101 102 103100 101 102 103
100 101 102 103100 101 102 103100 101 102 103
100
80
60
40
20
0
100
80
60
40
20
0
100
80
60
40
20
0
80
60
40
20
0
100
80
60
40
20
0
60
40
20
0
40
20
30
10
0
0
200
400
600
800
1000
FS
C
600 800400 10002000
FSC TOF
101 102 103100
CFSE
0
200
400
600
800
1000
FS
C 
(c)
1:1 2:1 4:1No Treg
CFSE suppress ion
Medium
DAC (1 휇M)
Control
0
20
40
60
80
%
 d
iv
id
in
g 
re
sp
on
de
r c
ell
s
(d)
Figure 2: Eﬀect of DAC on proliferation and suppressive capacity of CD4+ Treg. (a) Representative dot plots, showing the expression of Ki67
in αCD3/αCD28+ 100U rIL-2 stimulated FACS-sorted Tconv and Treg at day 8 of culture. (b) Cumulative data showing the percentage of
Ki67-positive cells in Tconv and Treg stimulated in the presence or absence of 1μM DAC for 8 days (n = 7). (c) Eﬀect of DAC on the
suppressive capacity of CD4+ Treg. Flow cytometry of a CFSE-based suppression assay of αCD3/αCD28+ 100 U IL-2-stimulated Treg that
were cultured for 8 days in the presence or absence of 1 μM DAC. (d) Cumulative data showing the percentage dividing responder cells in
the presence of Treg with or without DAC. N = 3. Mean ± SD are shown. (b, c) Wilcoxon signed-rank test, 2-tailed, ∗p < 0 05
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population with low FOXP3 expression (FOXP3low) and
high FOXP3 expression (FOXP3high) can be identiﬁed [4]
(Figure 3(d)). We wondered if cytokine production was
associatedwith the FOXP3 expression levels and subsequently
analyzed the cytokine-producing potential in FOXP3low
and FOXP3high CD4+ cells. No diﬀerences were found in
cytokine expression between FOXP3low and FOXP3high cells
(Figure 3(d)).
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Figure 3: Eﬀect of DAC on cytokine-producing potential of CD4+ Treg and Tconv. Flow cytometric analysis of αCD3/αCD28+ 100U
rIL-2-stimulated FACS-sorted Treg and Tconv in the absence or presence of 1 μM of DAC, at day 8 of culture. The cytokine-
producing potential was analyzed following 4 h stimulation with PMA/ionomycin in the presence of Brefeldin A. (a) Gating strategy.
(b) Representative dot plots showing IFNγ-, IL-17a-, and IL-10-producing Treg and Tconv that were cultured in the presence or absence
of DAC. (c) Cumulative data on IFNγ-, IL-17a-, and IL-10-producing Treg and Tconv after culture in the presence of absence of 1 μM
DAC. (d) IFNγ production in FOXP3− and FOXP3+ Treg, representative dot plots, and cumulative data are shown. Mean ± SD are shown.
N = 6, Wilcoxon signed-rank test, 2-tailed. ∗p < 0 05.
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3.4. Regulatory T Cells Polarize towards a Th1-like Phenotype
upon DAC Treatment. Analysis of the expression levels of
the chemokine receptors CXCR3, CCR6, and CCR4
enables further characterization of peripheral blood
Thelper-like subsets [35–37]. Th1-like cells are contained
within the CXCR3+ cell population, while Th17-like and
Th2-like cells are contained within CXCR3−CCR4+CCR6+
and CXCR3−CCR4+CCR6− cell populations, respectively.
Following DAC treatment of stimulated Treg and Tconv,
an increase in CXCR3-expressing cells was observed in both
Treg (medium 20.72%± 9.357 versus DAC 36.89%± 8.518,
p = 0 0313) and Tconv (medium 20.69%± 8.729 versus
DAC 28.44%± 6.712, p = 0 0625 (NS)) (Figure 4). To con-
ﬁrm strong Th1 polarization by DAC in CD4+ T cells, we
analyzed the expression of the Th1 master transcription
factor Tbet by RT-qPCR after stimulation of isolated CD4+
T cells in the absence or presence of DAC. Supplementation
of DAC led to a signiﬁcant increase in TBX21 (encoding
Tbet) mRNA expression (medium 0.045± 0.0107) versus
DAC 0.1422± 0.0275, p = 0 0313), while mRNA expression
of the prototypic Th17 transcription factor RORC was not
inﬂuencedbyDAC.Togetherwith theaboveobserved increase
in IFNγ expression, this suggests that DAC favors diﬀerentia-
tion towards a Th1-like phenotype. DAC did not signiﬁcantly
inﬂuence Th2- and Th17-associated marker expression.
To conﬁrm strong Th1 polarization by DAC in CD4+
T cells, we analyzed the expression of the Th1 master
transcription factor Tbet by RT-qPCR after stimulation
of isolated CD4+ T cells in the absence or presence of
DAC. Supplementation of DAC led to a signiﬁcant increase
in TBX21 (encoding Tbet) mRNA expression (medium
0.045± 0.0107) versus DAC 0.1422± 0.0275, p = 0 0313),
while mRNA expression of the prototypic Th17 transcription
factor RORC was not inﬂuenced by DAC. Together
with the above observed increase in IFNγ expression,
this suggests that DAC favors diﬀerentiation towards a
Th1-like phenotype.
3.5. The Eﬀect of DAC on Treg under Proinﬂammatory
Conditions. Previously, we showed that IL-17A production
by Treg was increased under proinﬂammatory conditions,
which could be prohibited by treatment with epigenetic
modiﬁers, like trichostatin A [4]. Here, we examined
whether DAC had similar eﬀects. To mimic a proinﬂam-
matory condition, rIL-1β was added on day 0 to cultures
of CD3/CD28 bead and rIL-2-stimulated Treg (Tconv
were included for comparison) and IL-17A, IFNγ, and
IL-10 expression was analyzed on day 8 by ﬂow cytometry.
DAC led to a signiﬁcant increase of the IFNγ-producing
capacity in both Treg (medium 7.32%± 5.53 versus
DAC 15.40%± 9.76, p = 0 0313) and Tconv (medium
11.58%± 17.56 versus DAC 23.57%± 22.41, p = 0 0313).
Also, a signiﬁcant increase in IL-10 was observed under
these conditions in both Treg (medium 4.40%± 2.30 ver-
sus DAC 7.30%± 4.36) and Tconv (medium 1.23%± 1.26
versus DAC 3.27%± 3.42). The eﬀect of DAC on IL-17A
production by Treg was only apparent in three high
producers of IL-17A (>10% IL-17A-producing cells follow-
ing IL-1β stimulation); here, DAC treatment led to
inhibition of IL-17A expression. In the low IL-17A pro-
ducers as well as in Tconv, no eﬀect was seen (Figure 5).
3.6. In Vivo 5-Azacitidine (Vidaza) Has the Potential to
Promote IFNγ Expression in Patients with Hematological
Malignancies. DAC-based demethylating agents are used
to treat hematological conditions such as MDS, AML,
and CMML. Previous studies on in vivo treatment with
AZA/DAC in these patients reported conﬂicting observa-
tions with respect to the eﬀect of AZA/DAC on Treg
numbers and cytokine production [23, 26, 36]. To support
our in vitro ﬁndings, we performed an ex vivo analysis of
peripheral blood T cells in 14 patients with MDS, AML,
and CMML that were treated with Vidaza, for 7 consecu-
tive days, every 28 days. Peripheral blood samples were
analyzed for intracellular FOXP3 and IFNγ, IL-17a, and
IL-10 expression by CD3+CD8− cells (“CD4+ cells”) and
CD3+CD8−FOXP3+ T cells using ﬂow cytometry.
Vidaza treatment resulted in an increased FOXP3
expression level in 10 out of 14 patients after 7 days of
treatment. Seven of these patients were still participating
in the study after 5 cycles of Vidaza treatment; 4 out of
7 patients showed an increased FOXP3 expression level
(NS) (Figures 6(a) and 6(b)). After 7 days of treatment,
IFNγ expression was increased in 6 out of 11 patients in
both CD4+ cells and CD4+FOXP3+ cells; however, this
was not signiﬁcant. After 5 cycles, 4 of 6 patients show
an increase in IFNγ expression in both CD4+ and CD4+-
FOXP3+ cells (NS). IL-10- and IL-17a-producing capacity
is decreased in the majority of patients. IL-10 was
decreased in 6/11 patients after 7 days and in 4/6 after 5
cycles, both in CD4+ and CD4+FOXP3+. IL-17a was
decreased in 8/11 patients after 7 days and in 4/6 patients
after 5 months (NS) (Figures 6(c) and 6(d)).
The increased expression levels of FOXP3 (MFI) and
IFNγ observed in the majority of patients resembled the
in vitro data. The diﬀerences in FOXP3 expression and
cytokine production were not correlated with the clinical
outcomes such as survival, hematological improvement,
or transfusion response.
4. Discussion
Promoting Treg numbers and improving their stability
appear an attractive approach to prevent inﬂammation in a
variety of immunopathogenic processes [40–43] and is con-
sidered a means to prevent myelosuppression and ineﬀective
hematopoiesis in patients with hematological malignancies
[33, 34]. In these patients, the immune system is changed,
as for example indicated by clonal expansion of CD4+ and
CD8+ T cells and variable numbers of Treg depending on dis-
ease severity [30–32]. The DNMT inhibitors Aza and DAC,
which seemingly have the potential to promote FOXP3
expression [15, 17, 21, 22], are therapeutically used in MDS,
AML, and CMML patients to reduce uncontrolled myelodys-
plasia and increased survival of the patients [34, 44]. This
DAC treatment also inﬂuences the immune system of the
treated patients as indicated by changes in Thelper cells,
regulatory T cells, and the CD4/CD8 T cell composition
7Journal of Immunology Research
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Figure 4: Continued.
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[23, 26, 36]. Variation in Treg numbers in peripheral blood of
MDS patients has been reported [30–32], and expansion of
Treg in high-risk MDS correlates with a poor prognosis
[35], suggesting that Treg play a role in this disease. It is
not known if DAC aﬀects human naturally occurring
FOXP3+ Treg in their function.
In the presented work, we demonstrate that supplemen-
tation of DAC to in vitro cultures of naturally occurring Treg
induces increased FOXP3 expression levels without inﬂuenc-
ing Helios expression levels. DAC inhibits Treg proliferation;
yet, DAC-treated Treg maintain their suppressor capacity.
However, even though DAC-treated Treg cells are still sup-
pressive, DAC-treated Treg increase their IFNγ-producing
potential. Under inﬂammatory conditions, not only did
both Tconv and Treg upregulate IFNγ but also IL-10
was signiﬁcantly increased upon DAC supplementation.
Increased FOXP3 expression levels and IFNγ production
were also observed in patients treated with Vidaza.
It has previously been shown that Treg numbers are sig-
niﬁcantly increased in high-risk MDS, whereas in low-risk
MDS IL-17-producing CD4+ T cells were increased, which
suggests an association between the number of Treg and
Th17 and disease severity [31, 35]. Expansion of regulatory
T cells occurs in high-risk MDS and correlates with a poor
prognosis [35]. We here show that although DAC supple-
mentation supports Treg suppressor functions, it inhibits
Treg proliferation, which might contribute to the mechanism
of action of DAC in high-risk MDS. However, in various
inﬂammatory mouse models for diabetes, multiple sclerosis,
lung inﬂammation, and GVHD, Treg numbers were
increased. Increased Treg numbers were designated as the
mechanism to prevent immune pathology [17, 19–22, 45].
In one study, it was shown that Treg from DAC-treated mice
revealed increased in vitro suppressive potential [19], while
other studies failed to demonstrate the increased suppressive
capacity by Treg from DAC-treated mice [7, 15]. Conﬂicting
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Figure 4: Eﬀect of DAC on chemokine receptor expression of CD4+ Treg and Tconv. Flow cytometry of αCD3/αCD28+ 100 U
IL-2-stimulated FACS-sorted Treg and Tconv on day 8 of culture. (a) Gating strategy and deﬁnition of Th1/Th2/Th17(like) Tconv and
Treg. (b) Representative dot plots of Th1/Th2/T17(like) cells of Tconv and Treg that were cultured in the presence or absence of
DAC. (c) CXCR3+ cells (Th1), CXCR3−CCR4+CCR6− cells (Th2), and CXCR3−CCR4+CCR6+ cells (Th17) N = 4 – 5, Wilcoxon
signed-rank test, 2-tailed. ∗p < 0 05. (d) RT-qPCR analysis of TBX21 (Tbet) and RORC expression in isolated CD4+ cells stimulated with
αCD3/αCD28+ 100U rIL-2 in the absence or presence of 1μM of DAC, on day 4 of culture. The samples were normalized to the
CT values of human HPRT1 (endogenous control), and 2
−ΔCT values are displayed. N = 5 Wilcoxon signed-rank test, 2-tailed, ∗p < 0 05
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Figure 5: Eﬀect of DAC on cytokine-producing potential of CD4+ Treg under proinﬂammatory conditions. Flow cytometric analysis of
αCD3/αCD28+ 100U IL-2 + 50 ng/mL IL-1β-stimulated FACS-sorted Treg and Tconv on day 8 of culture. The cytokine-producing
potential was analyzed following 4 h stimulation with PMA/ionomycin in the presence of Brefeldin A. Cumulative data on IFNγ-, IL-17a-,
and IL-10-producing Treg and Tconv that were cultured in the presence or absence of 1μM DAC. Mean ± SD are shown. N = 6,
Wilcoxon signed-rank test, 2-tailed. ∗p < 0 05
9Journal of Immunology Research
CD45
FS
C
FS
C
CD4
93.52 59.05
FOXP3
8.23%
MFI 2.30
1000
800
600
400
200
0
1000
1000
1500
800
600
400
200
0
500
0
0 100 101 102 103100 101 102 103100 101 102 103
(a)
FOXP3 7 days FOXP3 MFI 7 daysFOXP3 5 months FOXP3 MFI 5 months
−10
−5
0
5
10
∆ 
FO
XP
3 
ex
pr
es
sio
n
−20
−10
0
10
20
∆ 
FO
XP
3 
ex
pr
es
sio
n
−3
−2
−1
0
1
2
3
∆ 
FO
XP
3 
M
FI
 ex
pr
es
sio
n
−1.0
−0.5
0.0
0.5
1.0
∆ 
FO
XP
3 
M
FI
 ex
pr
es
sio
n
(b)
FS
C
CD3 IL-10
FS
C
FS
C
IF
N
훾
IL-17
IF
N
훾
84.98
55.68
0.08 5.26
0.75
7.69 0.32 0.95
0.53
92.55
100
101
102
103
100
101
102
103
100
101
102
103
100
101
102
103
100 101 102 103
1000
800
600
400
200
0
1000
800
600
400
200
0
0 100 101 102 103 100 101 102 103
100 101 102 103 100 101 102 103 1000 101 102 103
CD45
400 8001000200 6000400 8001000200 6000
SSC
0
CD
8
0
200
400
600
800
1000
FS
C
0
200
400
600
800
1000
FS
C
FOXP3 IL-10 IL-17
(c)
CD4+  FOXP3+
IFN훾 7 days IFN훾 5 months IFN훾 7 days IFN훾 5 months
IL-17a 7 daysIL-17a 7 days IL-17a 5 months IL-17a 5 months
IL-10 7 days IL-10 5 monthsIL-10 5 months
−20
−10
0
10
20
∆ 
IF
N
훾
 ex
pr
es
sio
n
−40
−20
0
20
40
∆ 
IF
N
훾
 ex
pr
es
sio
n
−15
−10
−5
0
5
10
15
∆ 
IF
N
훾
 ex
pr
es
sio
n
−20
−10
0
10
20
∆ 
IF
N
훾
 ex
pr
es
sio
n
−3
−2
−1
0
1
2
3
∆ 
IL
-1
7a
 ex
pr
es
sio
n
−4
−2
0
2
4
∆ 
IL
-1
7a
 ex
pr
es
sio
n
−10
−5
0
5
10
∆ 
IL
-1
7a
 ex
pr
es
sio
n
−4
−2
0
2
4
∆ 
IL
-1
7a
 ex
pr
es
sio
n
−4
−2
0
2
4
6
∆ 
IL
-1
0 
ex
pr
es
sio
n
−50
−5
0
5
50
100
∆ 
IL
-1
0 
ex
pr
es
sio
n
−2
−1
0
1
2
3
∆ 
IL
-1
0 
ex
pr
es
sio
n
−1.5
−1.0
−0.5
0.0
0.5
1.0
5
10
∆ 
IL
-1
0 
ex
pr
es
sio
n
(d)
Figure 6: In vivo eﬀect of Vidaza treatment on FOXP3 expression and cytokine expression by CD4 T cells. Flow cytometry of isolated PBMCs
obtained from Vidaza-treated patients with hematological malignancies. (a) Gating strategy used for FOXP3 analyses. (b) Diﬀerence (Δ) in
percentage FOXP3+ cells and MFI after 7 days (short term) (N = 11) and after 5 cycles (long term) (N = 7) of Vidaza. (c) Gating strategy used
for cytokine analysis in CD4+ and CD4+FOXP3+ T cells after 4 h PMA/ionomycin stimulation in the presence of Brefeldin A. (d) Diﬀerence
(Δ) in percentage of IFNγ, IL-17A, and IL-10 in CD4+ T cells and CD4+FOXP3+ Treg after 7 days and 5 cycles of Vidaza. Paired t-test, no
signiﬁcant diﬀerences.
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observations were reported regarding the eﬀect of DAC on
Treg numbers in vivo in humans; Costantini et al. [26] and
Bontkes et al. [36] reported that 9 months (68 patients) or
3 months (9 patients) of DAC treatment of MDS patients
did not result in an increase of FOXP3-expressing cells, while
Stübig et al. [23] and Schroeder et al. [25] found increased
Treg numbers in AML, CMML, and MDS patients.
In our patient study, we studied 14 patients. In these
patients, the majority, 10 out of 14, showed an increase in
FOXP3 expression after 7 days of treatment, but after 6
months this eﬀect was no longer evident. From our data, it
seems that the eﬀect exerted by DAC on Treg in vivo is
mainly a short-term eﬀect and not a persisting long-term
eﬀect. This is supported by the studies of Stübig et al. [23]
and Schroeder et al. [25], which reveal that measuring rela-
tively early after DAC/Aza treatment results in increased
FOXP3 expression levels, while the studies of Costantini
et al. [26] and Bontkes et al. [36], which measure after a pro-
longed treatment, did not reveal diﬀerences in FOXP3
expression levels. This might also explain diﬀerences in the
outcome between the diﬀerent studies. It should however
be noted that we cannot rule out that the short-term increase
in the prevalence of FOXP3+ T cells is the result of transient
FOXP3 expression by activated CD4+ T cells. Given the
above information, it is not likely that Treg numbers and/or
stability is crucial for the long-term successful DAC eﬀects
in hematological malignancies.
Inhibition of proliferation of Tconv is one of the mecha-
nisms by which Treg exert their immune suppressive eﬀect.
We here demonstrate that Treg, which were cultured in the
presence of DAC, maintained their suppressive potential,
while culture of Tconv in the presence of DAC does not con-
fer suppressor potential despite the fact that these cells
showed an increased FOXP3 expression following DAC
treatment, such as that also reported by Kehrmann et al.
[24]. This is in contrast to the observations by Lal et al.
[15], who showed that DAC-treated Tconv did become sup-
pressive. Notably, at present there is much debate on the
association of FOXP3 expression in Tconv and their immune
suppressive potential [46].
In vitro, we observed an increased IFNγ expression upon
DAC and Vidaza treatment, suggesting that reduced methyl-
ation promotes the IFNγ-producing capacity of T cells. After
5 months of treatment, this was also seen ex vivo in patients
with hematological malignancies, in 4 out of 6 patients. This
is in line with ﬁndings in mice, showing that deletion of the
Dnmt1 gene that promotes reduced methylation led to an
upregulation of cytokine-encoding genes including IFNγ in
mouse T cells [47, 48]. Vice versa, in mice it was shown that
increased methylation inhibits IFNγ transcription in T cells
[49]. Regarding the eﬀect of DAC on IFNγ expression by
human T cells, it was observed that DAC led to an increase
in IFNγ-expressing CD4+ T cells in vitro in T cells iso-
lated from MDS patients but not in cells isolated from
healthy donors [26]. In myelodysplasia patients treated
with DAC, IFNγ expression by CD4+ T cells was not
promoted [26, 36]. In two in vitro studies, contradictory
observations were reported with respect to the eﬀect of
DAC on IFNγ expression in healthy donors [23, 36]. Our
study demonstrates that DAC promotes IFNγ expression
upon in vitro activation of Tconv obtained from healthy
donors. Moreover, in our study, we demonstrate for the ﬁrst
time that this is also the case for Treg. Despite the increased
IFNγ expression following in vitro stimulation of naturally
occurring Treg in the presence of DAC, the Treg maintained
their suppressor potential and also still produce IL-10. It has
been demonstrated before that expression of proinﬂamma-
tory cytokines by Treg does not hamper their suppressor
capacity in vivo [50]. In fact, recently it has been demon-
strated that Th1-like Treg are crucial for the protection of
diabetes in a mouse model [51]. Th1-like Treg were also
observed in MS patients; next to IFNγ, an increase in IL-10
by these cells was observed [50].
Based on chemokine expression proﬁles, diﬀerent
Thelper populations have been described in Treg and
Tconv [52]. We here demonstrate that next to an increase
in IFNγ expression, also the percentages of CXCR3+ Thelper
1-like Treg and Tconv were increased following DAC supple-
mentation in vitro. Additional to the increase in IFNγ follow-
ing DAC supplementation, we observed a trend towards
increased IL-10 expression by Treg and Tconv. It has been
previously postulated that IL-10 is frequently coproduced
with IFNγ in Th1-like Treg populations [52], while con-
ventional Th1 cells rarely produce IL-10 [52]. However,
under proinﬂammatory stimulatory conditions (i.e., anti-
CD3/CD28 beads, IL-2, and IL-1β), we observed that
DAC supplementation led to a signiﬁcant increase in IL-10
expression by CD4+ Tconv and Treg. The increase in IL-10
was not observed in patients, which might be due to the
limited numbers of Treg in peripheral blood and the
limited IL-10 expression of freshly isolated cells.
Whether AZA/DAC has a proinﬂammatory or anti-
inﬂammatory outcome seems to depend on the nature of
the disease, disease state, and dosing of the drug. More
research in this ﬁeld is necessary to ﬁnd the optimal treat-
ment regimen for cancer patients and to further explore
possibilities of using DNMT is in inﬂammatory diseases.
In conclusion, the DNMT inhibitor DAC promotes
Th1 polarization of Treg in vitro. In vivo, a similar
increase in IFNγ was observed. Despite the upregulation
of IFNγ and the inhibition of proliferation, Treg do main-
tain their suppressive capacity. This might be due to the
increased production of IL-10. The outcome of AZA/
DAC treatment seems to be dependent on a delicate bal-
ance between proinﬂammatory and anti-inﬂammatory
processes and cytokines produced.
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Supplementary Materials
Supplemental Figure 1: FACS settings and gating strategy of
CD4+ Treg and Tconv. (A) Gating strategy used for FACS
and rerun of CD4+CD25high-sorted cells; %CD4+CD25+-
FOXP3+ after sorting (day 0). (B) Gating strategy. Sorted
Tconv (CD25−) and Treg (CD25high) cells are gated on
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CD45+ and CD4+ to analyze the expession of FOXP3 and
CD25. Supplemental Figure 2: eﬀect of DAC on viability of
CD4+ Treg and Tconv. Flow cytometric analysis of αCD3/
αCD28+ 100U rIL-2 stimulated CD4+CD25high (Treg) and
CD4+CD25− (Tconv) FACS-sorted T cells at day 8 of culture.
Mean± SD is shown. Dose-response curve showing the eﬀect
of increasing concentrations of DAC (x-axis) on the viability
of Treg and Tconv as determined by labelling with the Fix-
able Viability Dye eFluor 780 (y-axis) (n = 2). Supplemental
Table 1: patient characteristics. (Supplementary Materials)
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